BRIDGEPOINT takes majority stake in GBA GROUP

The investment fund Bridgepoint signed an agreement in July 2026 to acquire a majority stake in GBA Group, backing the laboratory testing platform in a secondary buyout transaction from Ardian. The primary shareholding reorganization sees the exiting financial sponsor liquidate the vast majority of its equity position, while GBA Group's executive leadership team executes a significant management roll-over to remain coinvested alongside the new financial backer. From an industrial perspective, the strategic rationale centers on consolidating the target's market penetration across high-growth environmental, food, and life sciences end markets. The sponsor aims to accelerate the platform's global expansion via selective buy-and-build add-on acquisitions, continuing the external growth trajectory that previously incorporated 19 strategic acquisitions under prior ownership. Capital allocation under the new ownership will prioritize the expansion of domestic and cross-border testing capacities, investments in laboratory infrastructure, workflow automation, and digital solutions including AI-enabled services. The deal execution mobilizes an extensive multi-disciplinary advisory consortium. On the buy-side, Bridgepoint mandated Citi and DC Advisory as co-lead M&A advisors, with Rothschild providing additional M&A advisory services. Strategic and commercial due diligence was completed by Boston Consulting Group (BCG), while EY handled the financial and tax audit scopes, and Latham & Watkins acted as primary legal counsel. On the sell-side, Ardian engaged Macquarie and Morgan Stanley as financial M&A advisors. LEK conducted commercial due diligence, with EY performing the vendor financial due diligence (FDD), Taxess directing tax structuring, and Milbank managing the legal perimeter. Subject to customary antitrust clearances and regulatory closing conditions, final completion of the transaction is slated for the end of 2026.